We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.85
Bid: 2.70
Ask: 3.00
Change: 0.00 (0.00%)
Spread: 0.30 (11.111%)
Open: 2.85
High: 2.85
Low: 2.85
Prev. Close: 2.85
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EU Patent Office grants patent for MCT

2 Nov 2016 07:00

RNS Number : 0525O
Allergy Therapeutics PLC
02 November 2016
 



2 November 2016

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

 

European Patent Office grants new and expanded patent underpinning Allergy Therapeutics' core Microcrystalline Tyrosine technology

 

Patent already granted in the United Kingdom and New Zealand

 

Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, today announces that the European Patent Office has granted a broad technology patent relating to the Company's unique Microcrystalline Tyrosine (MCT) depot adjuvant manufacturing process. This patent covers the novel manufacture and physiochemical characteristics of MCT in combination with one or more antigens, further strengthening the Company's core intellectual property.

 

The granting of this patent further strengthens Bencard Adjuvant Systems, the wholly-owned division of Allergy Therapeutics which specialises in developing and optimising aluminium-free adjuvants for infectious diseases. Recent data generated have shown how MCT has a synergistic effect when coupled with another adjuvant from BAS's portfolio, Virus Like Particles (VLP), to create the adjuvant system AdSys-VcT. As recently announced, this adjuvant system demonstrated protective efficacy in a malaria model in a study performed in collaboration with the University of Oxford, UK.

 

Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: "We are pleased to expand this key patent and are excited by the potential for MCT as a core technology within our adjuvant portfolio to create novel and efficacious vaccines, both in allergies and also in infectious disease areas such as malaria and influenza. This further underpins the future pipeline for products, and the long term success of Allergy Therapeutics to continue innovating and producing novel medicines."

 

ENDS

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director

 

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

 

Consilium Strategic Communications

 

+44 20 3709 5700

Mary-Jane Elliott / Ivar Milligan

allergytherapeutics@consilium-comms.com

 

Notes for editors:

 

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease. The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities. The Company employs c.420 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

 

About Bencard Adjuvant Systems

Bencard Adjuvant Systems (BAS) is a division of Allergy Therapeutics UK. Located in UK, BAS specialises in developing and optimising adjuvants for vaccines against infectious diseases and allergen immunotherapy. The team at BAS are committed to engaging in long-term partnerships with those who require BAS's patented platform of adjuvant technologies to enable successful vaccine or immunotherapy development. For more information, please contact www.bencard-as.com.

 

About Microcrystalline Tyrosine

Microcrystalline Tyrosine (MCT) functions as a depot adjuvant in the Company's range of subcutaneous immunotherapy products. The use of a depot upon which to attach an antigen facilitates recognition by the immune system by providing a slow release system and thus extending the time available for the immune system to process the antigen. MCT is comprised of defined crystalline particles of the amino-acid L-Tyrosine, which is naturally biodegraded by the body and further used in biological functions. MCT offers a shorter solubility profile being metabolised in 48 hours1 and also exhibits a favourable immune profile in that it preferentially shifts from an allergic Th1 response to a tolerating Th2 response2 both of which are preferential to classic depot adjuvants such as aluminium in short-course allergen immunotherapy.

 

References

1 Baldrick et al, J of toxicology, 2002.

2Kundig et al., pending publication.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUGGACGUPQPUG
Date   Source Headline
3rd Apr 20247:00 amRNSDirector Resignation
27th Mar 20247:00 amRNSUpdate on funding
27th Mar 20247:00 amRNSInterim Results for six months ended 31 Dec 2023
12th Mar 20248:59 amRNSVLP Peanut PROTECT Trial Update
12th Mar 20247:00 amRNSVLP Peanut PROTECT Trial Update
11th Mar 20247:00 amRNSAppointment of Shaun Furlong to Board of Directors
8th Mar 20241:49 pmRNSResult of AGM
14th Feb 20247:00 amRNSHalf-Year Trading Update 2024
9th Feb 20243:07 pmRNSNotice of 2023 Annual General Meeting
30th Jan 20247:30 amRNSRestoration - Allergy Therapeutics plc
30th Jan 20247:00 amRNSPublication of Annual Report and Accounts 2023
4th Jan 202412:29 pmRNSTotal Voting Rights
2nd Jan 20247:30 amRNSSuspension - Allergy Therapeutics plc
27th Dec 202312:01 pmRNSAmendment to existing Facility Agreement
15th Dec 202312:48 pmRNSAnnual Report and Accounts Delayed
13th Dec 20234:54 pmRNSPDMR dealing and Total Voting Rights
13th Dec 20237:00 amRNSG306 Phase III trial meets key endpoints
11th Dec 20237:00 amRNSUpdate on funding
1st Dec 20237:00 amRNSTotal Voting Rights
28th Nov 20233:03 pmRNSHolding(s) in Company
14th Nov 20237:00 amRNSG306 Grass Phase III trial meets primary endpoint
10th Nov 20232:39 pmRNSForm 8.5 (EPT/RI)
10th Nov 20231:22 pmRNSDirector/PCA Dealing
10th Nov 20231:11 pmRNSHolding(s) in Company
10th Nov 20237:00 amRNSOffer Closure
9th Nov 202310:48 amRNSExercise of Options and Total Voting Rights
9th Nov 20239:24 amRNSForm 8.5 (EPT/RI)
9th Nov 20239:15 amRNSForm 8.5 (EPT/NON-RI)
8th Nov 202310:45 amRNSForm 8.5 (EPT/RI)
7th Nov 202311:10 amRNSForm 8.5 (EPT/RI)
6th Nov 20239:33 amRNSForm 8.5 (EPT/RI)
6th Nov 20237:00 amRNSUpdate on funding
3rd Nov 20239:31 amRNSForm 8.5 (EPT/RI)
2nd Nov 202310:24 amRNSForm 8.5 (EPT/RI)
1st Nov 202310:23 amRNSForm 8.5 (EPT/RI)
31st Oct 20238:30 amRNSForm 8.5 (EPT/RI)
30th Oct 202310:06 amRNSForm 8.5 (EPT/RI)
27th Oct 202311:33 amRNSForm 8.5 (EPT/RI)
26th Oct 202310:07 amRNSForm 8.5 (EPT/RI)
25th Oct 20239:48 amRNSForm 8.5 (EPT/NON-RI)
25th Oct 20238:43 amRNSForm 8.5 (EPT/RI)
24th Oct 20238:29 amRNSForm 8.5 (EPT/RI)
23rd Oct 20238:23 amRNSForm 8.5 (EPT/RI)
20th Oct 20235:17 pmRNSHolding(s) in Company
20th Oct 20239:02 amRNSForm 8.5 (EPT/RI)
19th Oct 20238:38 amRNSForm 8.5 (EPT/RI)
19th Oct 20237:00 amRNSPosting of Offer Document
18th Oct 20238:34 amRNSForm 8.5 (EPT/RI)
17th Oct 202310:31 amRNSForm 8.5 (EPT/RI)
16th Oct 20235:39 pmRNSSouthern Fox: Form 8.3 – Allergy Therapeutics Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.